Latest Johnson & Johnson News & Updates

See the latest news and media coverage for J&J. We track all announcements, press releases, and industry mentions in real time, all in one place.

Johnson & Johnson (J&J)

Multinational healthcare company

Latest news about Johnson & Johnson (J&J)

Today J&J

J&J announces CAPLYTA shows greatest efficacy in MDD meta-analysis

CAPLYTA ranked highest across four efficacy measures and showed no weight gain versus placebo plus ADT in network meta-analysis presented at NEI Congress.
May 1 J&J

FDA approves STELARA for pediatric Crohn’s disease

Approval on April 15, 2026, for patients 2+ with moderately to severely active CD. First non-TNF biologic for this group based on Phase 3 UNITI-Jr study.
April 29 J&J

J&J presents over 20 studies at ASCO 2026

Data include late-breaking Phase 3 PROTEUS for ERLEADA and MajesTEC-9 results for TECVAYLI, spanning prostate, multiple myeloma, head and neck, lung, colorectal, and bladder cancers.
April 27 J&J

J&J announces FDA Priority Review for IMAAVY in wAIHA

The review shortens timeline to six months based on pivotal ENERGY study showing durable hemoglobin response and fatigue improvement. IMAAVY targets underlying IgG autoantibodies.

May 1 MedTech Intelligence

Johnson & Johnson Enters Agreement to Acquire Atraverse Medical

The deal would fold the FDA-cleared Hotwire system, and the team behind Farapulse, into J&J's expanding cardiac ablation business.
May 1 MassDevice

Johnson & Johnson has a new VP of investor relations

Johnson & Johnson (NYSE:JNJ) announced that it appointed Ryan Koors to the role of VP, investor relations (IR).
April 30 Fierce Biotech

J&J axes $5B CAR-T dream months after touting best-in-disease efficacy

Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north of $5 billion.
April 30 The BMJ

Johnson & Johnson talcum powder cancer case is heard in UK High Court

The largest product liability case in UK legal history—with more than 7000 potential claimants—reached the High Court in ...

Never miss news about J&J

Track J&J and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Discover what's making headlines across other trending companies.